Otros idiomas Harrow, Inc.

Acciones

HROW

US4158581094

Mercado cerrado - OTC Markets Otros sitios de cotización 22:00:00 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
10,19 ^USD	-4,05 %		-1,26 %	-9,02 %

11/04	HARROW, INC. : Craig-Hallum tiene una opinión positiva	ZM
22/03	HARROW, INC. : B. Riley reitera su recomendación de compra	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024	26/04
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing	03/04
Top Midday Decliners	20/03
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results	20/03
Harrow, Inc. Provides Earnings Guidance for the Year 2024	20/03
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	20/03
North American Morning Briefing : Markets on Hold as Fed Decision Nears	20/03
Harrow : Q4-2023 Letter to Stockholders	19/03
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Restore stock falls as weak tech trading drags down annual results	14/03
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results after Market Close on March 19, 2024	06/03
Harrow Announces New Appointments to its Board of Directors	30/01
Harrow, Inc. Announces Board of Director Appointments	29/01
Harrow Announces Availability of VEVYE 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	12/01
Harrow Health's Eye Treatment Drug Vevye Now Available in US	11/01
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	11/01
Harrow Partners with Leading Healthcare Market Access Technology Platforms	04/01
Melt Pharmaceuticals Provides Corporate Update	04/01
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	03/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Harrow, Inc.

Acciones

HROW

US4158581094

Otros idiomas

Filtros